Evidence map›Paper›PMID 42638627›Full record

ArticleFrontiers in tuberculosis2023

Efficacy of RUTI

Pablo Soldevilla, Anna Buisan, Jorge Diaz, Sergi Saladrigas, Yaiza Rosales, Lilibeth Arias, Alexandra Jimenez-Melsio, Cristina Vilaplana, Merce Amat Fabregat, Pere-Joan Cardona

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in tuberculosis, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Pablo SoldevillaUnitat de Tuberculosi Experimental, Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain.
Anna BuisanArchivel Farma, s.l., Badalona, Spain.
Jorge DiazServei de Microbiologia, Laboratori Clínic de la Metropolitana Nord (LCMN), Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
Sergi SaladrigasArchivel Farma, s.l., Badalona, Spain.
Yaiza RosalesCentre de Medicina Comparativa i Bioimatge de Catalunya (CMCiB), Badalona, Spain.
Lilibeth AriasUnitat de Tuberculosi Experimental, Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain.
Alexandra Jimenez-MelsioArchivel Farma, s.l., Badalona, Spain.
Cristina VilaplanaUnitat de Tuberculosi Experimental, Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain.
Merce Amat FabregatArchivel Farma, s.l., Badalona, Spain.
Pere-Joan CardonaUnitat de Tuberculosi Experimental, Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: The objective of this study was to evaluate the safety and efficacy of the therapeutic vaccine RUTI Methods: We assessed the efficacy of RUTI Results: RUTI Discussion: Therapeutic vaccination against TB has been avoided for decades due to fear of toxicity through the Koch phenomenon. These data show for the first time the safety of immunotherapy with Mtb antigens in an active TB model, adding efficacy to SOC. This encourages the beginning of clinical studies to evaluate the safety and efficacy of RUTI

Indexed as

chemotherapyimmunotherapyKoch phenomenonMycobacterium tuberculosisRUTI®

Identifiers

PMID42638627
PMCPMC13494941

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.